We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+23.93%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$389M
AUM Growth
+$159M
Cap. Flow
+$127M
Cap. Flow %
32.66%
Top 10 Hldgs %
65.31%
Holding
60
New
19
Increased
8
Reduced
9
Closed
22

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.1M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$14.6M
3
AKAO
Achaogen Inc
AKAO
+$11M
4
KYNB
Kyntra Bio
KYNB
+$9.16M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.63M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$12.9M
2
PFE icon
Pfizer
PFE
+$11.8M
3
KITE
Kite Pharma, Inc.
KITE
+$10.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.78M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$7.83M

Sector Composition

Rank Sector Weight
1 Healthcare 50.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADXS
51
DELISTED
Advaxis Inc
ADXS
– –
-16,800
Closed -$1.64M
SBBP
52
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-66,756
Closed -$477K
RARX
53
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-102,054
Closed -$1.91M
DERM
54
DELISTED
Dermira, Inc.
DERM
– –
-120,600
Closed -$3.51M
ARRY
55
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-800,000
Closed -$6.7M
TSRO
56
DELISTED
TESARO, Inc.
TSRO
– –
-9,300
Closed -$1.15M
KITE
57
CALL
DELISTED
Kite Pharma, Inc.
KITE
– –
-110,000
Closed -$11.4M
KITE
58
DELISTED
Kite Pharma, Inc.
KITE
– –
-100,000
Closed -$10.4M
CELG
59
DELISTED
Celgene Corp
CELG
– –
-99,110
Closed -$12.9M
NDRM
60
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-327,240
Closed -$9.78M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Nexthera Capital held 60 positions worth $389M, up 69% from $230M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Nexthera Capital deployed $127M of net new capital in Q3 2017, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 373,000 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 71% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $7.83M trimmed.

  • Nexthera Capital's largest Q3 2017 buy was Seagen Inc. Common Stock: 373,000 shares worth $20.3M.
  • Nexthera Capital added most to Dova Pharmaceuticals, Inc. Common Stock in Q3 2017, an estimated $5.69M increase.
  • Nexthera Capital's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $7.83M.
  • Nexthera Capital fully exited Celgene Corp in Q3 2017, selling an estimated $12.9M.
  • Nexthera Capital's ten largest holdings make up 65% of its $389M portfolio in Q3 2017.
  • Nexthera Capital opened 19 new positions and closed 22 in Q3 2017.
  • Nexthera Capital's portfolio value rose 69% quarter-over-quarter to $389M.

Based on Nexthera Capital's 13F filing for Q3 2017, filed 14 Nov 2017.